NKIO Seed
London, GB · 3 known investors
Find your way into NKIO Seed
242 people in our graph share verified history with the NKIO Seed team — schools, employers, funds. One of them is your warm intro.
Ben Perryunlockedknows Andrew Baxendale · together at UCB (overlapped)
×4knows the team · via GSK
×5knows the team · via University of Hertfordshire
knows the team · via UCB
knows the team · via Nottingham Trent University
NK:IO develops natural killer (NK) cell and small molecule therapies for cancer, targeting both haematological and solid tumours such as ovarian cancer. Its platform technologies, based on umbilical cord blood stem cells, aim to expand NK cells and enhance their tumour-killing capacity for cancer immunotherapy, with programmes at the research and early preclinical stage.
Founders & leadership
HB
Hugh BradyCo-founder
MJ
Matthew J. FuchterCo-founder
AB
Andrew BaxendaleinAndrew Baxendale brings over 30 years of experience in drug discovery and development across pharma, biotech, and service sectors, with expertise in business development, licensing transactions, and fundraising. He has held leadership and board positions at biotech companies and has experience in therapeutic development across multiple phases.
Investors · 3
Frequently asked questions
- What does NKIO Seed do?
- NK:IO develops natural killer (NK) cell and small molecule therapies for cancer, targeting both haematological and solid tumours such as ovarian cancer. Its platform technologies, based on umbilical cord blood stem cells, aim to expand NK cells and enhance their tumour-killing capacity for cancer immunotherapy, with programmes at the research and early preclinical stage.
- Who founded NKIO Seed?
- NKIO Seed was founded by Hugh Brady, Matthew J. Fuchter.
- Who are NKIO Seed's investors?
- NKIO Seed's investors include Cambridge Angels group, Future Planet Capital, UK Innovation & Science Seed Fund.
- Where is NKIO Seed headquartered?
- NKIO Seed is headquartered in London, GB.